source
- Midsized biotechs press White House to drop CMS pricing rulesA number of midsized biotech companies have met with White House and HHS officials in the last week, presenting their case for why two pending CMS pricing models could hinder their business and sho…Endpoints · 13d ago↗ source
- Celcuity got its cancer drug approved. Then its stock dippedThe FDA’s approval for Celcuity’s cancer drug Revtorpyk on Tuesday was widely anticipated. What Wall Street didn’t expect was that the drug could take until the end of the quarter to launch. ...Endpoints · 13d ago↗ source
- Jasper gets a lifeline in merger with immune drugmaker KiraThe acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.